Keros Therapeutics, Inc.
KROS
$10.10
-$0.56-5.25%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -542.97% | -2,121.49% | 146.44% | 135.50% | 111.17% |
| Total Depreciation and Amortization | 17.65% | 20.99% | 22.78% | 25.96% | 30.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.70% | -24.51% | -15.26% | -4.75% | 10.13% |
| Change in Net Operating Assets | 390.55% | -229.25% | -5.89% | -281.62% | 74.50% |
| Cash from Operations | -187.20% | -227.49% | 166.83% | 163.28% | 138.27% |
| Capital Expenditure | 74.80% | 31.68% | 19.68% | 21.85% | 16.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 74.80% | 31.68% | 19.68% | 21.85% | 16.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.87% | -99.88% | -99.93% | -80.39% | 0.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 206.92% | 171.28% | 130.62% | 100.00% | 68.90% |
| Cash from Financing | -265.92% | -262.02% | -196.59% | -80.36% | 0.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -252.01% | -257.74% | -218.99% | -33.02% | 239.92% |